Volpara Health Technologies posted earning in line with expectation. Morgans highlights the importance and significance of the data that is being collected and moved into the cloud, being some 50m images.

This aids further development work in the early detection/prediction of breast cancer as well as monitoring changes over time, the broker notes, and the value of this data is ever-increasing.

Volpara remaisn on track to meet its FY22 revenue guidance. Add and $1.87 target retained.

Sector: Health Care Equipment & Services.

Target price is $1.87.Current Price is $1.10. Difference: $0.77 - (brackets indicate current price is over target). If VHT meets the Morgans target it will return approximately 41% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2021 Acquisdata Pty Ltd., source FN Arena